Visfatin Levels in Nonalcoholic Fatty Liver Disease

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 2, 2012, Pages 115-119

  Akbal, Erdem ^a   Koçak, Erdem ^a   Taş, Adnan ^a   Yüksel, Enver ^a   Köklü, Seyfettin ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Nonalcoholic fatty liver disease; Visfatin

Indexed keywords

AMINOTRANSFERASE; LIPID; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; MALE; NONALCOHOLIC FATTY LIVER;

ADULT; CASE-CONTROL STUDIES; DEMOGRAPHY; FATTY LIVER; FEMALE; HUMANS; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

EID: 84859168943     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21491     Document Type: Article

References (26)

1. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV. NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-924.
2. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 2010;51:500-506.
3. Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Ginés P, Colmenero J, Parola M, Gelmini S, Tarquini R, Laffi G, Pinzani M, Marra F. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006;169:2042-253.
4. Tilg H. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis. Curr Pharm Des 2010;16:1893-1895.
5. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-969.
6. Romanowska A, Lebensztejn DM. Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease. Pol Merkur Lekarski 2010;28:459-461.
7. Kukla M, Ciupińska-Kajor M, Kajor M, Wylezoł M, Zwirska-Korczala K, Hartleb M, Berdowska A, Mazur W. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol 2010;61:147-153.
8. Gaddipati R, Sasikala M, Padaki N, Mukherjee RM, Sekaran A, Jayaraj-Mansard M, Rabella P, Rao-Guduru V, Reddy-Duvvuru N. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol 2010;9:266-270.
9. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damås JK, Haaland T, Løberg EM, Arntsen B, Birkeland K, Bjøro K, Ulven SM, Konopski Z, Nebb HI, Aukrust P, Halvorsen B. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010;95:3039-3047.
10. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, Alvarez T, Pacheco D, González JM. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009;54:1772-1777.
11. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-421.
12. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430.
13. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;12:2708-2715.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
15. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
16. Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010;44:25-36.
17. Kang YS, Song HK, Lee MH, Ko GJ, Cha DR. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res Clin Pract 2010;89:141-149.
18. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165-3170.
19. Moschen AR, Gerner RR, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des 2010;16:1913-1920.
20. Arner P. Visfatin-a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:28-30.
21. de Luis DA, Ballesteros M, Ruiz E, Muñoz C, Penacho A, Iglesias P, Guzmán AL, Abreu C, Maldonado A, Delgado M, Martín LS, Puigdevall V, Romero E, Sagrado MG, Izaola O, Conde R. Mar Cordero y Rocio Aller, Grupo de Nutrición, Sociedad Castellano Leonesa de Endocrinología, diabetes y nutrición. Visfatin in obese patients, relation with cardiovascular risk factors, a cross sectional study. Med Clin (Barc) 2011;137:199-203.
22. de Luis DA, Aller R, Gonzalez Sagrado M, Conde R, Izaola O, Perez Castrillon JL, Romero E. Serum visfatin concentrations are related to dietary intake in obese patients. Ann Nutr Metab 2010;57:265-270.
23. de Luis DA, Izaola O, Conde R, Primo D, Sagrado MG, Aller R. Visfatin levels in female, morbid, nondiabetic obese patients after biliopancreatic diversion surgery. Surg Obes Relat Dis 2011; 7:195-198.
24. Babali{dotless} A, Cakal E, Purnak T, Bi{dotless}yi{dotless}koǧlu I, Cakal B, Yüksel O, Köklü S. Serum alpha-fetoprotein levels in liver steatosis. Hepatol Int 2009; 3:551-555.
25. Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS. Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 2007;17:45-56.
26. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD) Am J Gastroenterl 2007;12:2716-2717.